Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion ? results of the Austrian multi-centre randomized ReoPro-BRIDGING Study
| Autor: | Gerhard Bonner, Werner Benzer, Gottfried Sodeck, Kurt Huber, Birgit Heinisch, Ronald Hödl, Hans Domanovits, Mariann Gyöngyösi, Georg Gaul, Moritz Haugk, Anton N. Laggner, Dietmar Glogar, Johann Wojta |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Percutaneous Abciximab medicine.medical_treatment Myocardial Infarction Myocardial Reperfusion Coronary Angiography Electrocardiography Immunoglobulin Fab Fragments Bolus (medicine) Interquartile range Internal medicine Angioplasty Humans Medicine Myocardial infarction Angioplasty Balloon Coronary Vascular Patency Aged business.industry Coronary Stenosis Antibodies Monoclonal Length of Stay Middle Aged medicine.disease Combined Modality Therapy Cardiology Female Stents Cardiology and Cardiovascular Medicine business Perfusion Platelet Aggregation Inhibitors TIMI medicine.drug |
| Zdroj: | European Heart Journal. 25:2125-2133 |
| ISSN: | 0195-668X |
| DOI: | 10.1016/j.ehj.2004.09.018 |
| Popis: | Aims The aim of the ReoPro-BRIDGING Austrian multi-centre study was to investigate the effects of abciximab (ReoPro®) on early reperfusion in ST-elevation myocardial infarction prior to or during primary percutaneous coronary angioplasty (pPCI). Methods and results Fifty-five patients with STEMI were randomized either to start abciximab (0.25 mg/kg bolus followed by 10 I¼g/min infusion) during the organization phase for pPCI (Group 1, n =28) or immediately before pPCI (Group 2, n =27). The time between first bolus of abciximab and first balloon inflation of pPCI was 83±18 vs 21±13 min in Group 1 vs 2. The pre-pPCI ST-segment resolution (55±21.4% vs 42.4±18.2%, p =0.005), TIMI flow grade 3 (29% vs 7%, p =0.042), corrected TIMI frame count (58.4±32.7 vs 78.9±28.4 frame, p =0.018) %diameter stenosis (76.3 /63.5–100/ vs 100 /73.5–100/; median /interquartile range/, p =0.023), were significantly higher in Group 1 vs Group 2. Quantitative myocardial dye intensity measurement revealed a significantly higher grade of myocardial tissue perfusion (1 /0–9.25/ vs 0 /0–3.0/ grey pixel unit, p =0.048) in Group 1 before pPCI. Rapid release of cardiac enzymes was observed in Group 1 as compared with Group 2: rate of rise of CK was 210±209 vs 97±95 U/l/h ( p =0.015). QRS score indicated a smaller infarct size in Group 1 (4.8±3.8 vs 7.6±3.5, p =0.011) on day 7. Conclusion The use of abciximab in the organization phase for pPCI results in signs of early recanalization of the infarct-related artery and a subsequent improved myocardial tissue reperfusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|